The underestimation of familial ALS and counseling patients with sporadic ALS
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Amyotrophic lateral sclerosis (ALS), the most common degenerative disease of the adult motor neuron system, occurs sporadically in 90% to 95% of cases. This implies no affected relative and no association with 1 of the 3 western Pacific foci.1 While “any affected relative,” the opposite of “no affected relative,” might be considered the definition for familial ALS (fALS), 2 or more remotely related members of an extended family might have sporadic ALS (sALS) due to chance alone. Conversely, a case of sALS might be a case of fALS, not recognized as such because of an incomplete family history or incomplete penetrance in ancestors. Because most forms of fALS are autosomal dominant, making the distinction between fALS and sALS has profound implications in counseling relatives of patients with sALS. Discussions of clinical definitions of fALS have focused on 2 questions: the smallest number of affected relatives required to define fALS (2 or more?) and the degree of relatedness (first, second, any?).2
Footnotes
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the author, if any, are provided at the end of the editorial.
See page 17
- © 2013 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Articles
Hexanucleotide repeat expansions in C9ORF72 in the spectrum of motor neuron diseasesWouter van Rheenen, Marka van Blitterswijk, Mark H.B. Huisman et al.Neurology, July 25, 2012 -
Article
Comparative analysis of C9orf72 and sporadic disease in an ALS clinic populationMfon E. Umoh, Christina Fournier, Yingjie Li et al.Neurology, August 03, 2016 -
Article
Multiparametric MRI study of ALS stratified for the C9orf72 genotypePeter Bede, Arun L.W. Bokde, Susan Byrne et al.Neurology, June 14, 2013 -
Views & Reviews
C9orf72 and the Care of the Patient With ALS or FTDProgress and Recommendations After 10 YearsJennifer Roggenbuck et al.Neurology: Genetics, December 21, 2020